174 related articles for article (PubMed ID: 10748723)
1. Synthesis of cyclic oligopeptides containing an Arg-Gly-Asp (RGD) sequence.
Sofuku S; Hoshida A; Shimada T; Takada Y; Takakuwa T
Chem Pharm Bull (Tokyo); 1999 Dec; 47(12):1799-801. PubMed ID: 10748723
[TBL] [Abstract][Full Text] [Related]
2. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
Stavrakoudis A; Bizos G; Eleftheriadis D; Kouki A; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tsikaris V
Biopolymers; 2000-2001; 56(1):20-6. PubMed ID: 11582574
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD peptide analogues as antiplatelet antithrombotics.
Barker PL; Bullens S; Bunting S; Burdick DJ; Chan KS; Deisher T; Eigenbrot C; Gadek TR; Gantzos R; Lipari MT
J Med Chem; 1992 May; 35(11):2040-8. PubMed ID: 1597855
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation.
Jois SD; Tambunan US; Chakrabarti S; Siahaan TJ
J Biomol Struct Dyn; 1996 Aug; 14(1):1-11. PubMed ID: 8877556
[TBL] [Abstract][Full Text] [Related]
5. [The structure-antiaggregative activity relationship in a series of Arg-Gly-Asp analogs].
Mel'nik OV; Martinovich VP; Golubovich VP
Bioorg Khim; 2006; 32(2):137-43. PubMed ID: 16637284
[TBL] [Abstract][Full Text] [Related]
6. Novel Cu(II)-RGD-octapeptides: Synthesis, coordination mode, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and correlation of sequence with nano-structure.
Li N; Kang G; Gui L; Zhao M; Wang W; Zhang J; Yue YF; Peng S
Nanomedicine; 2011 Aug; 7(4):403-9. PubMed ID: 21272663
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Non-peptide RGD Mimics for Evaluation of Their Utility as Anti-platelet Agents.
Higuchi K; Hikita H; Murayama A; Yuri D; Kobayakawa N; Takahashi T; Kojima S; Ueno H; Hatakeyama T; Kato A; Tayu M; Oyama E; Sugiyama S; Ishii K; Takahashi H; Kawasaki T
Chem Pharm Bull (Tokyo); 2016; 64(12):1726-1738. PubMed ID: 27904082
[TBL] [Abstract][Full Text] [Related]
8. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies.
Pearson DA; Lister-James ; McBride WJ; Wilson DM; Martel LJ; Civitello ER; Dean RT
J Med Chem; 1996 Mar; 39(7):1372-82. PubMed ID: 8691467
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.
Müller G; Gurrath M; Kessler H
J Comput Aided Mol Des; 1994 Dec; 8(6):709-30. PubMed ID: 7738606
[TBL] [Abstract][Full Text] [Related]
10. Amino acids and peptides. XXVII. Solid phase synthesis of fibrinogen-related peptides with disulfide bond formed on solid support.
Kakiuchi M; Izuno Y; Maeda M; Ueda K; Fujiwara K; Kunitada S; Kawasaki K
Chem Pharm Bull (Tokyo); 1996 May; 44(5):1107-10. PubMed ID: 8689720
[TBL] [Abstract][Full Text] [Related]
11. On-resin head-to-tail cyclization of cyclotetrapeptides: optimization of crucial parameters.
Alcaro MC; Sabatino G; Uziel J; Chelli M; Ginanneschi M; Rovero P; Papini AM
J Pept Sci; 2004 Apr; 10(4):218-28. PubMed ID: 15119594
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-aggregatory activity of linear retro-inverso RGD peptides.
Dal Pozzo A; Fagnoni M; Bergonzi R; Vanini L; de Castiglione R; Aglio C; Colli S
J Pept Res; 2000 Jun; 55(6):447-54. PubMed ID: 10888201
[TBL] [Abstract][Full Text] [Related]
13. Solution stability of linear vs. cyclic RGD peptides.
Bogdanowich-Knipp SJ; Chakrabarti S; Williams TD; Dillman RK; Siahaan TJ
J Pept Res; 1999 May; 53(5):530-41. PubMed ID: 10424348
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg-Gly-Asp peptides.
Kini RM; Evans HJ
FEBS Lett; 1995 Nov; 375(1-2):15-7. PubMed ID: 7498466
[TBL] [Abstract][Full Text] [Related]
15. The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides.
Kostidis S; Stavrakoudis A; Biris N; Tsoukatos D; Sakarellos C; Tsikaris V
J Pept Sci; 2004 Aug; 10(8):494-509. PubMed ID: 15347137
[TBL] [Abstract][Full Text] [Related]
16. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation.
Ali FE; Bennett DB; Calvo RR; Elliott JD; Hwang SM; Ku TW; Lago MA; Nichols AJ; Romoff TT; Shah DH
J Med Chem; 1994 Mar; 37(6):769-80. PubMed ID: 8145226
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.
Cheng S; Craig WS; Mullen D; Tschopp JF; Dixon D; Pierschbacher MD
J Med Chem; 1994 Jan; 37(1):1-8. PubMed ID: 7507165
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel potent peptidyl platelet preserving agent: molecular design and biologic activity.
Ozeki E; Matsuda T
ASAIO Trans; 1990; 36(3):M562-4. PubMed ID: 2252751
[TBL] [Abstract][Full Text] [Related]
19. Cyclic aza-peptide integrin ligand synthesis and biological activity.
Spiegel J; Mas-Moruno C; Kessler H; Lubell WD
J Org Chem; 2012 Jun; 77(12):5271-8. PubMed ID: 22582818
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability.
Wang B; Wang W; Camenisch GP; Elmo J; Zhang H; Borchardt RT
Chem Pharm Bull (Tokyo); 1999 Jan; 47(1):90-5. PubMed ID: 9987829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
